Author

Yun Zhang

Institutions: Jiangsu Cancer Hospital, Nanjing Medical University

Observed institutions: BeiGene (China), Jiangsu Cancer Hospital, Nanjing Medical University

ORCID: 0000-0001-5346-0068

Observed ORCID: 0000-0001-5346-0068

OpenAlex ID: A5091972374

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

2023 · Yunpeng Yang, Jianji Pan, et al. · Cancer Cell · 259

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

2023 · Jianchun Duan, Yun Zhang, et al. · Cell Reports Medicine · 44

The Utility of 18 F-FDG-PET–CT Metabolic Parameters in Evaluating the Primary Tumor Aggressiveness and Lymph Node Metastasis of Nasopharyngeal Carcinoma

2024 · Yun Zhang, Yuxiao Hu, et al. · Clinical Medicine Insights Oncology · 9

Utility of 18 F-FDG PET/CT in Treatment Strategies for Patients With Cancer of Unknown Primary: A Single-Center, Retrospective Change-in-Management Study

2024 · Rong Huang, Yuxiao Hu, et al. · Clinical Medicine Insights Oncology · 4

Validation of the 2018 FIGO staging system for stage IIIC cervical cancer by determining the metabolic and radiomic heterogeneity of primary tumors based on 18F-FDG PET/CT

2024 · Yun Zhang, Yuxiao Hu, et al. · Abdominal Radiology · 1

18 F-FDG PET/CT Metabolic Characteristics of Nasopharyngeal Carcinoma Across AJCC/UICC TNM-8 and TNM-9 Staging Systems: A Retrospective Cross-Sectional Study

2026 · Yun Zhang, Yan Tang, et al. · Clinical Medicine Insights Oncology

Works count: 6

Citation count: 317

H-index: 4

I10-index: 2